1
|
The Pattern of Use, Effectiveness, and Safety of Gadoteric Acid (Clariscan) in Patients Undergoing Contrast-Enhanced Magnetic Resonance Imaging: A Prospective, Multicenter, Observational Study. CONTRAST MEDIA & MOLECULAR IMAGING 2021; 2021:4764348. [PMID: 34803545 PMCID: PMC8572637 DOI: 10.1155/2021/4764348] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Accepted: 09/21/2021] [Indexed: 11/25/2022]
Abstract
Objective Contrast-enhanced MR (CE-MR) imaging is often required to improve lesion detection and characterization and to increase diagnostic confidence. This study aimed to evaluate the safety and effectiveness, as well as the use pattern, of the macrocyclic gadolinium-based contrast agent Clariscan in real-world clinical practice in Korea. Materials and Methods This was a prospective, multicenter, observational study of patients undergoing CE-MR as part of routine clinical care at 6 university hospitals in Korea. Effectiveness was evaluated by determining diagnostic confidence and image quality; safety evaluation included the adverse event (AE) expression rate. Subgroup analyses were conducted by body regions of diagnosis (musculoskeletal, nervous system, others) and in pediatric patients (aged ≤7 years). Results From October 2019 to September 2020, 1,376 subjects were included in the study. The mean volume of Clariscan used was 0.26 mL/kg (0.13 mmol/kg). In the overall study population and in each subgroup, diagnostic confidence increased after contrast enhancement with Clariscan. Overall, image quality was excellent in 72.5% of subjects and good-to-adequate in 27.2%. Clariscan was well tolerated (14 AEs occurred in 10 subjects); all AEs were of mild severity. Subgroup analyses showed that the mean dose of Clariscan used was ≥0.1 mmol/kg for nervous system-related diagnoses (e.g., brain) and ≤0.1 mmol/kg for musculoskeletal and pediatric-related diagnoses. All musculoskeletal and pediatric examinations were provided with a smaller package of 5 mL Clariscan. By body region of MR examination, the most common region was the nervous system in 69.0%, musculoskeletal system in 13.6%, and reproductive system in 4.9%. Conclusions This study confirmed the use pattern of Clariscan and its excellent effectiveness and safety in the real-world clinical environment in Korea. The small-dose package indicated the possibility of increasing the convenience and efficiency of drug use.
Collapse
|
2
|
Braun J, Busse R, Darmon-Kern E, Heine O, Auer J, Meyl T, Maurer M, Hamm B, de Bucourt M. Baseline characteristics, diagnostic efficacy, and peri-examinational safety of IV gadoteric acid MRI in 148,489 patients. Acta Radiol 2020; 61:910-920. [PMID: 31739672 DOI: 10.1177/0284185119883390] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Magnetic resonance imaging (MRI) examinations with intravenous (IV) contrast are performed worldwide in routine daily practice. In order to detect and enumerate even rare adverse events (AE) and serious adverse events (SAE), and to relate them with patients' baseline characteristics and diagnostic effectiveness, high quantity sample size is necessary. PURPOSE To assess safety, diagnostic effectiveness, and baseline characteristics of patients undergoing IV gadoteric acid (Dotarem®) MRI in routine practice. MATERIAL AND METHODS Data from two observational post-marketing surveillance (PMS) databases compiled by 139 and 52 German centers in 2004-2011 and 2011-2013, respectively, were pooled, yielding data on a total of 148,489 patients examined over a 10-year period. Radiologists used a standardized questionnaire to report data including patient demographics, characteristics of MR examinations, and results in terms of diagnosis and patient safety. RESULTS Overall, 712 AEs were reported in 467 (0.3%) patients, mainly nausea (n = 224, 0.2%), vomiting (n = 29, <0.1%), urticaria (n = 20, <0.1%), and feeling hot (n = 13, <0.1%). AEs were considered related to gadoteric acid in 362 (0.2%) patients. Higher frequencies of AEs were observed among patients with a previous reaction to a contrast agent (2.0%), liver dysfunction (0.7%), bronchial asthma (0.7%), and a history of allergies (0.6%). There were 49 SAEs in 18 (<0.1%) patients, including two children. No fatal SAE was reported. Examinations were diagnostic in 99.8% of all patients, and image quality was excellent or good in 97.7% of the patients. CONCLUSION Gadoteric acid is a safe peri-examinational and effective contrast agent for MRI in routine practice.
Collapse
Affiliation(s)
- Joachim Braun
- Department of Radiology, Charité – University Medicine, Berlin, Germany
| | - Reinhard Busse
- Department of Health Care Management, Faculty of Economics and Management, Berlin University of Technology, Berlin, Germany
| | | | | | - Jonas Auer
- Department of Radiology, Charité – University Medicine, Berlin, Germany
| | - Tobias Meyl
- Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, University of Bern, Bern, Switzerland
| | - Martin Maurer
- Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, University of Bern, Bern, Switzerland
| | - Bernd Hamm
- Department of Radiology, Charité – University Medicine, Berlin, Germany
| | | |
Collapse
|
3
|
Farmakis SG, Hardy AK, Mahmoud SY, Wilson-Flewelling SA, Tao TY. Safety of gadoterate meglumine in children younger than 2 years of age. Pediatr Radiol 2020; 50:855-862. [PMID: 32055917 DOI: 10.1007/s00247-020-04626-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2019] [Revised: 12/16/2019] [Accepted: 01/21/2020] [Indexed: 02/04/2023]
Abstract
BACKGROUND Few studies on the safety of gadolinium-based contrast agents have been performed in children with even fewer focusing on children younger than 2 years of age. OBJECTIVE To assess the safety of gadoterate meglumine (Dotarem) in patients younger than 2 years of age by evaluating adverse events following contrast administration. MATERIALS AND METHODS Pediatric patients younger than 2 years of age undergoing magnetic resonance imaging (MRI) with and without contrast were prospectively enrolled and received a weight-based intravenous dose of gadoterate meglumine (0.1 mmol/kg). The occurrence of adverse events was assessed at the time of injection, 2 h after MRI, and by phone contact using a standard questionnaire 24 h after MRI. Adverse events were documented including the time of onset, duration of symptoms, intensity, causality and subsequent outcome. Descriptive statistics were used to characterize patient information. RESULTS One hundred fifty exams were completed in 150 patients (median age: 12.1 months, age range: 0.25-23 months; males: 56%). Almost all patients (97.3%) received sedation/anesthesia before and during MRI. Thirty-four adverse events were reported in 23 patients overall (15.3%; male: 73.9%; median age: 11 months, age range: 3-23 months). Within the initial 2 h after the injection, there was one report of transient flushing/warmth and one report of vomiting, the latter of which was related to drinking formula too soon after anesthesia. Twenty-two patients (14.7%), who had all received sedation/anesthesia, experienced minor adverse events within 24 h, most physiological. Fourteen patients (9.3%) reported emesis, eight (5.3%) reported transient flushing/warmth, seven (4.7%) reported nausea, one (0.7%) reported altered taste and one (0.7%) reported dizziness. No patient experienced anaphylaxis. Two patients (1.3%) reported allergic-like reactions, which consisted of wheezing or sneezing. CONCLUSION No patient experienced adverse events directly related to gadoterate meglumine. Only two adverse events were reported to have occurred in the initial 2 h after the exam, while the rest were reported on the 24-h follow-up call. The higher reported rate of adverse events in this study may be related to concomitant sedation/anesthesia as well as to overreporting from parents on the 24-h follow-up questionnaire. The study confirms a good safety profile for gadoterate meglumine in this very sensitive population.
Collapse
Affiliation(s)
- Shannon G Farmakis
- Department of Radiology, SSM Health Cardinal Glennon Children's Hospital, St. Louis University School of Medicine, 3635 Vista Avenue at Grand Boulevard, St. Louis, MO, 63110, USA.
| | - Anna K Hardy
- Department of Radiology, St. Louis University School of Medicine, St. Louis, MO, USA
| | | | | | - Ting Y Tao
- Department of Radiology, SSM Health Cardinal Glennon Children's Hospital, St. Louis University School of Medicine, 3635 Vista Avenue at Grand Boulevard, St. Louis, MO, 63110, USA
| |
Collapse
|
4
|
Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment. Magn Reson Imaging 2020; 70:1-4. [PMID: 32112811 DOI: 10.1016/j.mri.2020.02.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Revised: 02/20/2020] [Accepted: 02/21/2020] [Indexed: 11/21/2022]
Abstract
PURPOSE Nephrogenic system fibrosis (NSF) is a rare complication detected in patients with renal insufficiency exposed to gadolinium-based contrast agents (GBCAs). The aim of our study is to evaluate the prevalence of NSF in a cohort of patients on renal replacement treatment who underwent GBCA-enhanced magnetic resonance imaging (MRI). METHOD We retrospectively reviewed all the charts of kidney transplant (KT) recipients, patients on hemodialysis (HD) and peritoneal dialysis (PD) who received a uniform protocol for contrast material enhanced-MRI with gadoteric acid at our center from January 2004 to December 2017. RESULTS Three-hundred forty-four patients (44.1% on HD, 11.3% on PD and 44.4% KT recipients) underwent 551 gadoteric acid-enhanced MRI. The median age of the patients was 58 years (IQR, 45-70 years) and 65.1% were men. Sixty-three patients (18.3%) had skin punch biopsy after integumentary assessment performed by a dermatologist. No cases of NSF were detected after a median follow-up of 4.5 years (IQR, 1.9-8.2 years). During this period of observation, 116 (33.7%) patients died and 11 (3.1%) were lost at follow-up. CONCLUSIONS None of the patients exposed to gadoteric acid developed NSF. Our results, in line with more recent studies, suggest that the use of gadoteric acid, a macrocyclic GBCA, appears safe even in chronic kidney disease (CKD) patients receiving dialysis.
Collapse
|
5
|
Chang DH, Pracros JP. Safety of gadoterate meglumine in over 1600 children included in the prospective observational SECURE study. Acta Radiol 2019; 60:1450-1456. [PMID: 31027425 PMCID: PMC6826856 DOI: 10.1177/0284185119840649] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Background To date, few data on the safety profile of gadoterate meglumine in pediatric patients are available. Purpose To assess the safety profile of gadoterate meglumine in routine practice, to detect any case of nephrogenic systemic fibrosis (NSF) suspicion and to collect efficacy data. Material and Methods The pediatric population of the observational SECURE study comprised 1631 patients scheduled for contrast-enhanced magnetic resonance imaging (MRI) with gadoterate meglumine (dose: 0.1 mmol/kg). Risk factors, MRI types and immediate adverse events (AEs) were systematically recorded. Patients with moderate to severe renal impairment were followed up for at least 3 months for detection of any NSF suspicion. Efficacy was assessed by the on-site radiologist in terms of image quality and ability to come to diagnosis. Results The population included 106 children (6.5%) aged <2 years, 815 (50.0%) aged 2 to <12 years and 710 (43.5%) aged 12 to <18 years, with a mean (± SD) age of 10.2 (± 4.9) years. Central nervous system exploration was the most frequent MRI type (80.4%) and main risk factors were any stage of renal insufficiency (9.8%) and allergies (5.2%). Only one AE (vomiting) that was deemed doubtfully related to gadoterate meglumine was observed. No suspicions of NSF were reported. Good to very good image quality was obtained for 98.4% of pediatric patients and diagnosis was established in 99.6% of cases. Conclusion This study confirmed the good safety profile of gadoterate meglumine in routine practice in a large pediatric population. The study is registered on https://clinicaltrials.gov/ with the identifier NCT01523873.
Collapse
Affiliation(s)
- De-Hua Chang
- Department of Radiology, University Clinic of Cologne, Cologne, Germany
| | - Jean-Pierre Pracros
- Department of Pediatric Radiology, Women-Mother and Child Hospital, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
6
|
Blumfield E, Swenson DW, Iyer RS, Stanescu AL. Gadolinium-based contrast agents - review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients. Pediatr Radiol 2019; 49:448-457. [PMID: 30923876 DOI: 10.1007/s00247-018-4304-8] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Revised: 09/01/2018] [Accepted: 10/31/2018] [Indexed: 12/29/2022]
Abstract
Gadolinium has been used as a base for contrast agents in MRI for the last three decades. Numerous studies over the last 4 years have reported increased signal intensity in deep brain nuclei in non-contrast MRI images following gadolinium-based contrast agent (GBCA) administration. Pathology studies performed on adults and children, and rodent necropsy studies have also shown gadolinium deposition in brain and other tissues after GBCA administration. The purpose of this review was to summarize and discuss the knowledge gained from these reports and the relevance for imaging pediatric patients.
Collapse
Affiliation(s)
- Einat Blumfield
- Department of Radiology, Children's Hospital of Montefiore, Albert Einstein College of Medicine, 111E 210th St, Bronx, NY, 10461, USA.
| | - David W Swenson
- Department of Diagnostic Imaging, Alpert Medical School of Brown University, Rhode Island Hospital/Hasbro Children's Hospital, Providence, RI, USA
| | - Ramesh S Iyer
- Department of Radiology, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, USA
| | - A Luana Stanescu
- Department of Radiology, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, USA
| |
Collapse
|
7
|
The Critical Need for Pediatric and Juvenile Animal Research Addressing Gadolinium Retention in the Developing Body. Invest Radiol 2018; 54:72-75. [PMID: 30273280 DOI: 10.1097/rli.0000000000000516] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
8
|
Tamrazi B, Nguyen B, Liu CSJ, Azen CG, Nelson MB, Dhall G, Nelson MD. Changes in Signal Intensity of the Dentate Nucleus and Globus Pallidus in Pediatric Patients: Impact of Brain Irradiation and Presence of Primary Brain Tumors Independent of Linear Gadolinium-based Contrast Agent Administration. Radiology 2018; 287:452-460. [PMID: 29189102 PMCID: PMC5929364 DOI: 10.1148/radiol.2017171850] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Purpose To determine whether whole-brain irradiation, chemotherapy, and primary brain pathologic conditions affect magnetic resonance (MR) imaging signal changes in pediatric patients independent of the administration of gadolinium-based contrast agents (GBCAs). Materials and Methods This institutional review board-approved, HIPAA-compliant study included 144 pediatric patients who underwent intravenous GBCA-enhanced MR imaging examinations (55 patients with primary brain tumors and whole-brain irradiation, 19 with primary brain tumors and chemotherapy only, 52 with primary brain tumors without any treatment, and 18 with neuroblastoma without brain metastatic disease). The signal intensities (SIs) in the globus pallidus (GP), thalamus (T), dentate nucleus (DN), and pons (P) were measured on unenhanced T1-weighted images. GP:T and DN:P SI ratios were compared between groups by using the analysis of variance and were analyzed relative to group, total cumulative number of doses of GBCA, age, and sex by using multivariable linear models. Results DN:P ratio for the radiation therapy group was greater than that for the other groups except for the group of brain tumors treated with chemotherapy (P < .05). The number of GBCA doses was correlated with the DN:P ratio for the nontreated brain tumor group (P < .0001). The radiation therapy-treated brain tumor group demonstrated higher DN:P ratios than the nontreated brain tumor group for number of doses less than or equal to 10 (P < .0001), whereas ratios in the nontreated brain tumor group were higher than those in the radiation therapy-treated brain tumor group for doses greater than 20 (P = .05). The GP:T ratios for the brain tumor groups were greater than that for the neuroblastoma group (P = .01). Conclusion Changes in SI of the DN and GP that are independent of the administration of GBCA occur in patients with brain tumors undergoing brain irradiation, as well as in patients with untreated primary brain tumors. © RSNA, 2017.
Collapse
Affiliation(s)
- Benita Tamrazi
- From the Departments of Radiology (B.T., B.N., C.S.J.L., C.G.A., M.D.N.) and Hematology (M.B.N., G.D.), Children’s Hospital Los Angeles, 4650 Sunset Blvd, MS 81, Los Angeles, CA 90027
| | - Binh Nguyen
- From the Departments of Radiology (B.T., B.N., C.S.J.L., C.G.A., M.D.N.) and Hematology (M.B.N., G.D.), Children’s Hospital Los Angeles, 4650 Sunset Blvd, MS 81, Los Angeles, CA 90027
| | - Chia-Shang J. Liu
- From the Departments of Radiology (B.T., B.N., C.S.J.L., C.G.A., M.D.N.) and Hematology (M.B.N., G.D.), Children’s Hospital Los Angeles, 4650 Sunset Blvd, MS 81, Los Angeles, CA 90027
| | - Colleen G. Azen
- From the Departments of Radiology (B.T., B.N., C.S.J.L., C.G.A., M.D.N.) and Hematology (M.B.N., G.D.), Children’s Hospital Los Angeles, 4650 Sunset Blvd, MS 81, Los Angeles, CA 90027
| | - Mary B. Nelson
- From the Departments of Radiology (B.T., B.N., C.S.J.L., C.G.A., M.D.N.) and Hematology (M.B.N., G.D.), Children’s Hospital Los Angeles, 4650 Sunset Blvd, MS 81, Los Angeles, CA 90027
| | - Girish Dhall
- From the Departments of Radiology (B.T., B.N., C.S.J.L., C.G.A., M.D.N.) and Hematology (M.B.N., G.D.), Children’s Hospital Los Angeles, 4650 Sunset Blvd, MS 81, Los Angeles, CA 90027
| | - Marvin D. Nelson
- From the Departments of Radiology (B.T., B.N., C.S.J.L., C.G.A., M.D.N.) and Hematology (M.B.N., G.D.), Children’s Hospital Los Angeles, 4650 Sunset Blvd, MS 81, Los Angeles, CA 90027
| |
Collapse
|
9
|
Scala M, Koob M, de Buttet S, Bourrinet P, Felices M, Jurkiewicz E. A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years. Invest Radiol 2018; 53:70-79. [PMID: 28906338 PMCID: PMC5768226 DOI: 10.1097/rli.0000000000000412] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Accepted: 07/22/2017] [Indexed: 01/31/2023]
Abstract
OBJECTIVES The primary objective of this study was to investigate the pharmacokinetic profile of gadoterate meglumine in pediatric patients younger than 2 years; the secondary objectives were to document its efficacy and safety. MATERIAL AND METHODS This was a Phase IV open-label, prospective study conducted in 9 centers (4 countries). Forty-five patients younger than 2 years with normal estimated glomerular filtration rate and scheduled to undergo routine gadolinium-enhanced magnetic resonance imaging (MRI) of any organ were included and received a single intravenous injection of gadoterate meglumine (0.1 mmol/kg). To perform the population pharmacokinetics analysis, 3 blood samples per subject were drawn during 3 time windows at time points allocated by randomization. RESULTS Gadoterate meglumine concentrations were best fitted using a 2-compartmental model with linear elimination from central compartment. The median total clearance adjusted to body weight was estimated at 0.06 L/h per kg and increased with estimated glomerular filtration rate according to a power model. The median volume of distribution at steady state (Vss) adjusted to body weight was estimated at 0.047 L/kg. Estimated median terminal half-life (t1/2β) was 1.35 h, and the median systemic exposure (area under the curve) was 1591 μmol h/L. Efficacy was assessed by comparing precontrast +postcontrast images to precontrast images in a subset of 28 subjects who underwent an MRI examination of brain, spine, and associated tissues. A total of 28 lesions were identified and analyzed in 15 subjects with precontrast images versus 30 lesions in 16 subjects with precontrast + postcontrast images. Lesion visualization was improved with a mean (SD) increase in scores at subject level of 0.7 (1.0) for lesion border delineation, 0.9 (1.6) for internal morphology, and 3.1 (3.2) for contrast enhancement. Twenty-six adverse events occurred postinjection in 13 subjects (28.9%), including 3 serious reported in 1 subject (2.2%). One subject (2.2%) experienced 1 rash of moderate intensity considered as related to gadoterate meglumine. CONCLUSIONS The pharmacokinetic profile of gadoterate meglumine after a single intravenous injection of 0.1 mmol/kg was appropriately described in newborns and infants younger than 2 years, for whom no dose adjustment is required. The improved efficacy of gadoterate meglumine for contrast-enhanced MRI examination of brain, spine, and associated tissues, as well as its good safety profile, was also demonstrated in this population.
Collapse
Affiliation(s)
- Mario Scala
- From the *Med. Campus IV–Institute of Pediatric and Gynecologic Radiology and Med. Campus III–Central Radiology Institute, Kepler University Hospital, Linz, Austria; †Pediatric Radiology, Hautepierre Hospital, Strasbourg, France; ‡Guerbet, Roissy CDG Cedex, France; §Phinc, Massy, France; and ∥Department of Diagnostic Imaging, Children's Memorial Health Institute, Warszawa, Poland
| | - Meriam Koob
- From the *Med. Campus IV–Institute of Pediatric and Gynecologic Radiology and Med. Campus III–Central Radiology Institute, Kepler University Hospital, Linz, Austria; †Pediatric Radiology, Hautepierre Hospital, Strasbourg, France; ‡Guerbet, Roissy CDG Cedex, France; §Phinc, Massy, France; and ∥Department of Diagnostic Imaging, Children's Memorial Health Institute, Warszawa, Poland
| | - Sophie de Buttet
- From the *Med. Campus IV–Institute of Pediatric and Gynecologic Radiology and Med. Campus III–Central Radiology Institute, Kepler University Hospital, Linz, Austria; †Pediatric Radiology, Hautepierre Hospital, Strasbourg, France; ‡Guerbet, Roissy CDG Cedex, France; §Phinc, Massy, France; and ∥Department of Diagnostic Imaging, Children's Memorial Health Institute, Warszawa, Poland
| | - Philippe Bourrinet
- From the *Med. Campus IV–Institute of Pediatric and Gynecologic Radiology and Med. Campus III–Central Radiology Institute, Kepler University Hospital, Linz, Austria; †Pediatric Radiology, Hautepierre Hospital, Strasbourg, France; ‡Guerbet, Roissy CDG Cedex, France; §Phinc, Massy, France; and ∥Department of Diagnostic Imaging, Children's Memorial Health Institute, Warszawa, Poland
| | - Mathieu Felices
- From the *Med. Campus IV–Institute of Pediatric and Gynecologic Radiology and Med. Campus III–Central Radiology Institute, Kepler University Hospital, Linz, Austria; †Pediatric Radiology, Hautepierre Hospital, Strasbourg, France; ‡Guerbet, Roissy CDG Cedex, France; §Phinc, Massy, France; and ∥Department of Diagnostic Imaging, Children's Memorial Health Institute, Warszawa, Poland
| | - Elzbieta Jurkiewicz
- From the *Med. Campus IV–Institute of Pediatric and Gynecologic Radiology and Med. Campus III–Central Radiology Institute, Kepler University Hospital, Linz, Austria; †Pediatric Radiology, Hautepierre Hospital, Strasbourg, France; ‡Guerbet, Roissy CDG Cedex, France; §Phinc, Massy, France; and ∥Department of Diagnostic Imaging, Children's Memorial Health Institute, Warszawa, Poland
| |
Collapse
|
10
|
Turk O, Ozdemir NG, Atci IB, Saygi T, Yilmaz H, Antar V. Intraventricular Gadoteric Acid Intoxication: First Report. World Neurosurg 2018; 111:264-268. [PMID: 29292188 DOI: 10.1016/j.wneu.2017.12.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Revised: 12/19/2017] [Accepted: 12/20/2017] [Indexed: 10/18/2022]
Abstract
BACKGROUND Gadolinium-based contrast agents are relatively safe for use in magnetic resonance imaging (MRI) of nervous system pathology. Few reports have been reported regarding the severe adverse effects. These are mostly mild anaphylactoid reactions, especially in the vulnerable group. CASE DESCRIPTION We report a case of an adverse effect of gadoteric acid concerning the misuse as intraventricular administration. To our knowledge, this is the first report related to intraventricular spillage and its results. A 38-year-old male patient with a complaint of headache and drowsiness was admitted to the hospital, after which cranial MRI revealed that he had a posterior fossa mass. An operation was performed with the catheterization of the lateral ventricule as a safety device at the beginning, and later mass was evacuated gross totally. Frozen pathology result showed the tumor was medulloblastoma. On the first postoperative day a control contrasted cranial and total spinal MRI was planned. He was observed to have a tonic-clonic generalized seizure soon after returning to the ward. After giving the acute management with antiepileptics, the patient was stabilized and it was recognized that the patient was administered contrast media by the intraventricular route. Symptomatic treatment and cerebrospinal fluid irrigation by external ventricular drainage helped the patient's improvement. After a week his symptoms were relieved and he had no complications during outpatient controls. CONCLUSIONS In addition to formal basic supportive treatment, cerebrospinal fluid irrigation of the toxic contrast material is the best management method in case of such an unexpected misadministration of gadoteric acid.
Collapse
Affiliation(s)
- Okan Turk
- Department of Neurosurgery, Usak University Faculty of Medicine Education and Research, Usak, Turkey
| | - Nuriye G Ozdemir
- Department of Neurosurgery, Usak University Faculty of Medicine Education and Research, Usak, Turkey
| | - Ibrahim B Atci
- Department of Neurosurgery, Usak University Faculty of Medicine Education and Research, Usak, Turkey
| | - Tahsin Saygi
- Department of Neurosurgery, Usak University Faculty of Medicine Education and Research, Usak, Turkey
| | - Hakan Yilmaz
- Department of Neurosurgery, Usak University Faculty of Medicine Education and Research, Usak, Turkey.
| | - Veysel Antar
- Department of Neurosurgery, Usak University Faculty of Medicine Education and Research, Usak, Turkey
| |
Collapse
|
11
|
Soyer P, Dohan A, Patkar D, Gottschalk A. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study. J Magn Reson Imaging 2016; 45:988-997. [PMID: 27726239 PMCID: PMC6585792 DOI: 10.1002/jmri.25486] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2016] [Accepted: 09/08/2016] [Indexed: 01/01/2023] Open
Abstract
Purpose To investigate the safety of gadoterate meglumine and identify the incidence of nephrogenic systemic fibrosis (NSF). Materials and Methods An international prospective observational study was conducted from November 2008 to June 2013. A total of 35,499 adults and children who were scheduled to undergo contrast‐enhanced MRI using gadoterate meglumine were analyzed (female, 53.1%; mean age: 49.5 years; range: 0‐98 years). At least 3‐month follow‐up was planned for patients with an estimated creatinine clearance or glomerular filtration rate <60 mL/min (/1.73 m2) to detect any suspicion or occurrence of NSF. Adverse events (AEs) were prospectively recorded. Demographic data, risk factors, indications for MRI examinations, characteristics of gadoterate meglumine administration, and efficacy were documented. Results MRI examinations were mainly for central nervous system (61%). The most frequent risk factor was renal insufficiency (14.7%). Seventy AEs were observed in 44 patients (0.12%). Among the 70 AEs, 38 in 32 patients (0.09% of all patients) were considered related to gadoterate meglumine and classified as adverse drug reaction (ADR).The most frequent ADRs were urticaria (9 patients, 0.03%), nausea (7 patients, 0.02%), and vomiting (4 patients, 0.01%). Within the pediatric population (1,629 patients), only one AE (vomiting) was observed. Nine adult patients (0.03%) experienced serious AEs. Moderate to severe renal insufficiency at inclusion was reported in 514 patients (1.5%). Among them, 476 (92.6%) were followed‐up. No patients were suspected of having NSF and no cases of NSF were observed. Conclusion Our study confirms the excellent safety profile of gadoterate meglumine in routine practice. Level of Evidence: 1 J. Magn. Reson. Imaging 2017;45:988–997
Collapse
Affiliation(s)
- Philippe Soyer
- Department of Body and Interventional Imaging, Hôpital Lariboisiére, AP-HP, Paris, France.,Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France
| | - Anthony Dohan
- Department of Body and Interventional Imaging, Hôpital Lariboisiére, AP-HP, Paris, France.,Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France.,UMR INSERM 965, Hôpital Lariboisiére, Paris, France
| | - Deepak Patkar
- Department of Radiology, Nanavati Super Specialty Hospital, Mumbai, India
| | - Andreas Gottschalk
- Central Institute for Radiology and Neuroradiology, Krankenhaus Nordwest, Frankfurt am Main, Germany
| |
Collapse
|
12
|
Roberts DR, Chatterjee AR, Yazdani M, Marebwa B, Brown T, Collins H, Bolles G, Jenrette JM, Nietert PJ, Zhu X. Pediatric Patients Demonstrate Progressive T1-Weighted Hyperintensity in the Dentate Nucleus following Multiple Doses of Gadolinium-Based Contrast Agent. AJNR Am J Neuroradiol 2016; 37:2340-2347. [PMID: 27469211 DOI: 10.3174/ajnr.a4891] [Citation(s) in RCA: 90] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2016] [Accepted: 06/13/2016] [Indexed: 02/02/2023]
Abstract
BACKGROUND AND PURPOSE While there have been recent reports of brain retention of gadolinium following gadolinium-based contrast agent administration in adults, a retrospective series of pediatric patients has not previously been reported, to our knowledge. We investigated the relationship between the number of prior gadolinium-based contrast agent doses and increasing T1 signal in the dentate nucleus on unenhanced T1-weighted MR imaging. We hypothesized that despite differences in pediatric physiology and the smaller gadolinium-based contrast agent doses that pediatric patients are typically administered based on weighted-adjusted dosing, the pediatric brain would also demonstrate dose-dependent increasing T1 signal in the dentate nucleus. MATERIALS AND METHODS We included children with multiple gadolinium-based contrast agent administrations at our institution. A blinded reader placed ROIs within the dentate nucleus and adjacent cerebellar white matter. To eliminate reader bias, we also performed automated ROI delineation of the dentate nucleus, cerebellar white matter, and pons. Dentate-to-cerebellar white matter and dentate-to pons ratios were compared with the number of gadolinium-based contrast agent administrations. RESULTS During 20 years at our institution, 280 patients received at least 5 gadolinium-based contrast agent doses, with 1 patient receiving 38 doses. Sixteen patients met the inclusion/exclusion criteria for ROI analysis. Blinded reader dentate-to-cerebellar white matter ratios were significantly associated with gadolinium-based contrast agent doses (rs = 0.77, P = .001). The dentate-to-pons ratio and dentate-to-cerebellar white matter ratios based on automated ROI placement were also significantly correlated with gadolinium-based contrast agent doses (t = 4.98, P < .0001 and t = 2.73, P < .02, respectively). CONCLUSIONS In pediatric patients, the number of prior gadolinium-based contrast agent doses is significantly correlated with progressive T1-weighted dentate hyperintensity. Definitive confirmation of gadolinium deposition requires tissue analysis. Any potential clinical sequelae of gadolinium retention in the developing brain are unknown. Given this uncertainty, we suggest taking a cautious stance, including the use, in pediatric patients, of higher stability, macrocyclic agents, which in both human and animal studies have been shown to be associated with lower levels of gadolinium deposition, and detailed documentation of dosing. Most important, a patient should not be deprived of a well-indicated contrasted MR examination.
Collapse
Affiliation(s)
- D R Roberts
- From the Departments of Radiology and Radiological Sciences (D.R.R., A.R.C., M.Y., B.M., T.B., H.C., G.B.) .,Neurosciences and Neuroscience Research (D.R.R.)
| | - A R Chatterjee
- From the Departments of Radiology and Radiological Sciences (D.R.R., A.R.C., M.Y., B.M., T.B., H.C., G.B.)
| | - M Yazdani
- From the Departments of Radiology and Radiological Sciences (D.R.R., A.R.C., M.Y., B.M., T.B., H.C., G.B.)
| | - B Marebwa
- From the Departments of Radiology and Radiological Sciences (D.R.R., A.R.C., M.Y., B.M., T.B., H.C., G.B.)
| | - T Brown
- From the Departments of Radiology and Radiological Sciences (D.R.R., A.R.C., M.Y., B.M., T.B., H.C., G.B.)
| | - H Collins
- From the Departments of Radiology and Radiological Sciences (D.R.R., A.R.C., M.Y., B.M., T.B., H.C., G.B.)
| | - G Bolles
- From the Departments of Radiology and Radiological Sciences (D.R.R., A.R.C., M.Y., B.M., T.B., H.C., G.B.)
| | | | - P J Nietert
- Biostatistics (P.J.N.).,Public Health Sciences (P.J.N.), Medical University of South Carolina, Charleston, South Carolina
| | - X Zhu
- Department of Psychology (X.Z.), Normal College, Shihezi University, Xinjiang, China
| |
Collapse
|